Zentalis Pharmaceuticals ZNTL Stock
Zentalis Pharmaceuticals Price Chart
Zentalis Pharmaceuticals ZNTL Financial and Trading Overview
| Zentalis Pharmaceuticals stock price | 3.68 USD |
| Previous Close | 3.7 USD |
| Open | 3.73 USD |
| Bid | 2.63 USD x 200 |
| Ask | 4.54 USD x 200 |
| Day's Range | 3.51 - 3.74 USD |
| 52 Week Range | 1.13 - 6.95 USD |
| Volume | 685.89K USD |
| Avg. Volume | 2.05M USD |
| Market Cap | 261.25M USD |
| Beta (5Y Monthly) | 1.976 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.74 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.5 USD |
ZNTL Valuation Measures
| Enterprise Value | 88.15M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.3590517 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.4296845 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.623 |
Trading Information
Zentalis Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.976 |
| 52-Week Change | 171.85% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 6.95 USD |
| 52 Week Low | 1.13 USD |
| 50-Day Moving Average | 4.1 USD |
| 200-Day Moving Average | 2.51 USD |
ZNTL Share Statistics
| Avg. Volume (3 month) | 2.05M USD |
| Avg. Daily Volume (10-Days) | 782.33K USD |
| Shares Outstanding | 71.19M |
| Float | 48.97M |
| Short Ratio | 5.52 |
| % Held by Insiders | 22.44% |
| % Held by Institutions | 62.06% |
| Shares Short | 5.02M |
| Short % of Float | 8.83% |
| Short % of Shares Outstanding | 7.04% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.88% |
| Return on Equity (ttm) | -51.93% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -141476000 USD |
| Net Income Avi to Common (ttm) | -124133000 USD |
| Diluted EPS (ttm) | -1.74 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 211.76M USD |
| Total Cash Per Share (mrq) | 2.98 USD |
| Total Debt (mrq) | 38.65M USD |
| Total Debt/Equity (mrq) | 21.16 USD |
| Current Ratio (mrq) | 6.19 |
| Book Value Per Share (mrq) | 2.567 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -125567000 USD |
| Levered Free Cash Flow (ttm) | -81383000 USD |
Profile of Zentalis Pharmaceuticals
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 10275 Science Center Dr. |
| ZIP | 92121 |
| Phone | 858 263 4333 |
| Website | https://zentalis.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 106 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Q&A For Zentalis Pharmaceuticals Stock
What is a current ZNTL stock price?
Zentalis Pharmaceuticals ZNTL stock price today per share is 3.68 USD.
How to purchase Zentalis Pharmaceuticals stock?
You can buy ZNTL shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zentalis Pharmaceuticals?
The stock symbol or ticker of Zentalis Pharmaceuticals is ZNTL.
Which industry does the Zentalis Pharmaceuticals company belong to?
The Zentalis Pharmaceuticals industry is Biotechnology.
How many shares does Zentalis Pharmaceuticals have in circulation?
The max supply of Zentalis Pharmaceuticals shares is 71.19M.
What is Zentalis Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Zentalis Pharmaceuticals PE Ratio is now.
What was Zentalis Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Zentalis Pharmaceuticals EPS is -1.74 USD over the trailing 12 months.
Which sector does the Zentalis Pharmaceuticals company belong to?
The Zentalis Pharmaceuticals sector is Healthcare.
Zentalis Pharmaceuticals ZNTL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2310.38 USD — |
-1.07
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3090.39 USD — |
-0.26
|
— — | 3063.94 USD — | 3108.39 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}